Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
Open Access
- 12 June 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12), 4193
- https://doi.org/10.3390/ijms21124193
Abstract
Breast cancer (BCa) is one of the most predominantly diagnosed cancers in women. Notably, 70% of BCa diagnoses are Estrogen Receptor α positive (ERα+) making it a critical therapeutic target. With that, the two subtypes of ER, ERα and ERβ, have contrasting effects on BCa cells. While ERα promotes cancerous activities, ERβ isoform exhibits inhibitory effects on the same. ER-directed small molecule drug discovery for BCa has provided the FDA approved drugs tamoxifen, toremifene, raloxifene and fulvestrant that all bind to the estrogen binding site of the receptor. These ER-directed inhibitors are non-selective in nature and may eventually induce resistance in BCa cells as well as increase the risk of endometrial cancer development. Thus, there is an urgent need to develop novel drugs with alternative ERα targeting mechanisms that can overcome the limitations of conventional anti-ERα therapies. Several functional sites on ERα, such as Activation Function-2 (AF2), DNA binding domain (DBD), and F-domain, have been recently considered as potential targets in the context of drug research and discovery. In this review, we summarize methods of computer-aided drug design (CADD) that have been employed to analyze and explore potential targetable sites on ERα, discuss recent advancement of ERα inhibitor development, and highlight the potential opportunities and challenges of future ERα-directed drug discovery.Funding Information
- Canadian Cancer Society (706145)
This publication has 346 references indexed in Scilit:
- Estrogen synthesis and signaling pathways during aging: from periphery to brainTrends in Molecular Medicine, 2013
- Discovering Small-Molecule Estrogen Receptor α/Coactivator Binding Inhibitors: High-Throughput Screening, Ligand Development, and Models for Enhanced PotencyChemMedChem, 2011
- Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor‐Targeting PROTACsChemMedChem, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptorBioorganic & Medicinal Chemistry, 2008
- Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approachChemico-Biological Interactions, 2008
- Bicyclo[2.2.2]octanes: Close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivatorsBioorganic & Medicinal Chemistry Letters, 2007
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005
- The RXR heterodimers and orphan receptorsCell, 1995